Clinical Trials Browser

Phase 1 × Neoplasms × Lenalidomide × Clear all

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Phase 1 Completed

Neoplasms

NCT00046735 2019-11-18

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT01750983 2019-02-25

Ipilimumab and Lenalidomide in Advanced Cancer

Phase 1 Completed

Neoplasms